|By Business Wire||
|June 10, 2014 01:30 PM EDT||
Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Executive Chairman of its Board of Directors.
Hrusovsky brings more than twenty years of experience in life science and diagnostics industries. Prior to Quanterix, he was President of PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences (sold to PerkinElmer for $650M); and CEO of Zymark Corporation (sold to Caliper for $150M). Earlier Hrusovsky was President of FMC Corporation’s Pharmaceuticals and International Agricultural Products and prior to that held numerous management positions at DuPont. He currently serves on the board of directors of SynapDx, 908 Devices and Solect Energy.
Hrusovsky received his B.S. in Mechanical Engineering from Ohio State University and M.B.A. from Ohio University. He was awarded the 2013 Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions to life sciences and personalized medicine.
“I am very much compelled by the potential of Quanterix’ Simoa technology, the caliber of its board and leadership team and by the important opportunity to positively impact the world,” said Hrusovsky.
The appointment comes as Martin Madaus, formerly the Executive Chairman of the Board at Quanterix, is appointed Chairman and CEO of Ortho-Clinical Diagnostics (OCD) following the close of its acquisition from Johnson & Johnson by the Carlyle Group. Madaus will remain a member of Quanterix’ Board of Directors. “I couldn’t be more pleased that Kevin has accepted to become our new Executive Chairman at Quanterix,” said Madaus. “He is an outstanding leader with a strong track record for guiding innovative companies, creating value for shareholders and a great fit for Quanterix. Since the launch of the first Simoa products last year, the company has experienced rapid growth. Kevin’s leadership and experience will ensure the team at Quanterix has the support needed to continue that trajectory,” said Madaus.
To learn more about Simoa, please visit: www.quanterix.com.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Jul. 29, 2016 05:00 AM EDT Reads: 1,418
Jul. 29, 2016 04:45 AM EDT Reads: 2,560
Jul. 29, 2016 04:45 AM EDT Reads: 2,357
Jul. 29, 2016 04:30 AM EDT Reads: 1,394
Jul. 29, 2016 04:15 AM EDT Reads: 2,670
Jul. 29, 2016 03:45 AM EDT Reads: 1,036
Jul. 29, 2016 02:45 AM EDT Reads: 1,598
Jul. 29, 2016 02:30 AM EDT Reads: 1,456
Jul. 29, 2016 02:00 AM EDT Reads: 1,677
Jul. 29, 2016 12:30 AM EDT Reads: 1,700
Jul. 29, 2016 12:15 AM EDT Reads: 2,091
Jul. 29, 2016 12:15 AM EDT Reads: 1,993
Jul. 28, 2016 11:45 PM EDT Reads: 1,243
Jul. 28, 2016 10:15 PM EDT Reads: 2,228
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 28, 2016 10:15 PM EDT Reads: 1,444